We believe that EphA2 overexpression on exosomes is an effective biological vector for targeted inhibition of osteoclasts to help postmenopausal osteoporosis patients preserve bone mass while avoiding the side effects of bisphosphonates. Here, EPHA2 is linked to osteoporosis.